Former CMO and Execute VP of ASCO on Molecular Profiling in GI Cancer and Health Inequity

Video

Richard Schilsky, MD, touched on the research driving ASCO to award “Advance of the Year” to molecular profiling in gastrointestinal cancers, and what the organization’s top priorities are in the near future.

Richard Schilsky, MD, former Chief Medical Officer (CMO) and Executive Vice President of ASCO, spoke with CancerNetwork® about molecular profiling driving progress in gastrointestinal cancers, which was named ASCO’s Advance of the Year in “Clinical Cancer Advances 2021.”

Schilsky discussed the progress being made in this field and the top research contributing to the momentum in gastrointestinal cancers, while also elaborating on health equity in cancer research, ASCO’s top research priorities moving forward, and more.

He also explained the changes forced on clinical trials due to the coronavirus disease 2019 (COVID-19) pandemic, and how he anticipates trials can leverage these adjustments moving forward in a post-COVID world.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Related Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Related Content
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.

Pembrolizumab Combo Yields Significant OS in HER2+ Gastric/GEJ Cancer

May 2nd 2024
Article

The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Using FOLFIRI as a doublet with durvalumab or a triplet with durvalumab and tremelimumab yielded positive safety in gastric/GEJ cancers.

FOLFIRI Plus ICIs Display Anti-Tumor Activity in Gastric/GEJ Cancer

April 30th 2024
Article

Using FOLFIRI as a doublet with durvalumab or a triplet with durvalumab and tremelimumab yielded positive safety in gastric/GEJ cancers.

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial Updates

February 19th 2024
Podcast

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.

ASCO Guideline Issues Updated Systemic Therapy Recommendations in HCC

April 26th 2024
Article

Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.

ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC

ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC

April 23rd 2024
Article

ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.